19.02

1.76% -0.34

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $19.02, with a volume of 650.76K. It is down -1.76% in the last 24 hours and down -4.90% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Previous Close:

$19.36

Open:

$19.48

24h Volume:

650.76K

Relative Volume:

0.61

Market Cap:

$1.59B

Revenue:

Net Income/Loss:

$-230.32M

P/E Ratio:

-5.3944

EPS:

-3.5259

Net Cash Flow:

$-196.04M

1W Performance:

-3.35%

1M Performance:

-4.90%

6M Performance:

+19.92%

1Y Performance:

-65.44%

1-Day Range:

$18.82

$19.60

1-Week Range:

$18.50

$20.29

52-Week Range:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

130

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	19.02	1.59B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Upgrade	Wolfe Research	Underperform → Outperform
Mar-19-26	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Jan-15-26	Downgrade	Goldman	Neutral → Sell
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral
Sep-30-25	Downgrade	Citigroup	Buy → Neutral
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Sep-29-25	Downgrade	Jefferies	Buy → Hold
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-29-25	Downgrade	Stifel	Buy → Hold
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Jan-17-25	Upgrade	Goldman	Neutral → Buy
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

Jul 24, 2026

MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits

Jul 24, 2026

Jul 23, 2026

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits

Jul 23, 2026

Jul 21, 2026

Form 4 MoonLake Immunotherapeutics For: 21 July By Investing.com - Investing.com Canada

Jul 21, 2026

Jul 20, 2026

H.C. Wainwright reiterates Moonlake stock buy rating on funding By Investing.com - Investing.com South Africa

Jul 20, 2026

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits

Jul 20, 2026

H.C. Wainwright reiterates Moonlake stock buy rating on funding - Investing.com

Jul 20, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) CSO entity sells 16,105 shares - Stock Titan

Jul 20, 2026

MoonLake Immunotherapeutics CSO Kristian Reich sells 16,105 shares for $322,261.05 - Bitget

Jul 20, 2026

Jul 19, 2026

Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily

Jul 19, 2026

Jul 18, 2026

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits

Jul 18, 2026

Jul 17, 2026